4 September 2012 - Cyprotex (AIM:CRX), the specialist preclinical contract research organisation (CRO), today announces the resignation of Katya Tsaioun, PhD, with immediate effect.
Dr Tsaioun has served as Cyprotex's Chief Scientific Officer and Director since the August 2010 acquisition of its U.S based subsidiary Apredica, where she was President and co-founder.
As part of the Apredica purchase agreements, Dr. Tsaioun planned to remain with the combined companies for two years. During her tenure at Cyprotex, Dr, Tsaioun led Cyprotex into three new markets: high content in vitro toxicology, in vitro topical and cosmetic testing, and genomic ADME services.
The Company wishes to extend its gratitude for Dr. Tsaioun’s contributions as a Director and CSO and wishes her well in her future endeavours.
Cyprotex PLC Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel